YEAR-END REPORT 2007

 Research and development costs amounted to SEK 21.3 million in the full year 2007 (SEK 13.3 m for the period July-December 2006)
 The loss after tax was SEK -32.7 million in the full year 2007 (SEK -21.1 m for the period July-December 2006)
 Earnings per share were SEK -0.68 in the full year 2007 (SEK -0.78 for the period July-December 2006)
 The company had no net sales for the period
 Tripep secured a first EU patent on ribavirin as a vaccine adjuvant
 A phase I/II trial on Tripep’s ChronVac-C® vaccine began in the year
 Extraordinary General Meetings (EGM) on 19 December 2007 resolved to amend the Articles of Association and conduct a rights issue, which will raise the company some SEK 24.1 m before issue costs of about SEK 1.9 m
Events after the End of the Reporting Period
 Tripep filed a patent application for a new antibiotic-free formulation of ChronSeal in collaboration with Kringle Pharma Inc.
 First US patent secured for a new type of immunotherapy against HIV-1
 Tripep has filed an application with the Swedish Medical Products Agency to begin a phase II study on ChronSeal in collaboration with Kringle Pharma.

Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; the wound healing therapy ChronSeal, the therapeutic vaccine against Hepatitis C named ChronVac-C® plus the RAS® technology platform. The Tripep share is admitted to trade on First North.
Remium AB is certified adviser for Tripep AB.
For more information, please visit: www.tripep.se